Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech reports news on its commercial genetic-medicines business, led by VYJUVEK, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa. Company updates commonly cover VYJUVEK revenue and global commercialization, manufacturing and platform developments, and regulatory actions tied to its HSV-1-based gene delivery technology.
Recurring clinical and scientific updates address investigational programs including KB407 for cystic fibrosis, KB707 for advanced or metastatic non-small cell lung cancer, KB111 for Hailey-Hailey disease, KB803 for corneal abrasions in DEB patients, and additional HSV-1-based vectors. News also includes quarterly operating results, conference presentations, FDA designations, and investor-event participation.
Krystal Biotech (NASDAQ:KRYS) received United Kingdom MHRA marketing authorization for VYJUVEK to treat wounds in patients with dystrophic epidermolysis bullosa (DEB) with COL7A1 mutations, from birth. VYJUVEK is the first genetic medicine approved in the UK for DEB.
The approval includes flexible administration at home or in healthcare settings, including by patients or caregivers. VYJUVEK met UK Orphan Designation criteria, enabling up to 12 years of market exclusivity. Launch timing will depend on completion of reimbursement procedures.
Krystal Biotech (NASDAQ: KRYS) will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026 in Las Vegas. Krish S. Krishnan, chairman and CEO, will join a fireside chat at 11:20 am PT and hold investor meetings the same day. A webcast will be available beginning at 11:20 am PT on the company’s Investors website.
Krystal Biotech (NASDAQ: KRYS) reported $116.4 million in 1Q 2026 VYJUVEK global net product revenue and $1.0 billion in cash and investments at quarter end.
Clinical updates: KB803 enrollment complete (16 patients) with top-line IOLITE results expected 4Q 2026; KB801 enrollment ongoing with full enrollment of 60 patients and data expected by year-end. FDA granted platform technology designation to vectors for KB407 and KB111. FY2026 non-GAAP R&D+SG&A guidance: $175–$195 million.
Krystal Biotech (NASDAQ: KRYS) will present multiple programs at scientific conferences in May and June 2026. Presentations cover gene therapy vectors for primary ciliary dyskinesia, interim CORAL-1 cystic fibrosis results, and an inhaled HSV-based immunotherapy plus pembrolizumab in NSCLC.
Slides and posters will be posted to the company’s Investor website after each conference.
Krystal Biotech (NASDAQ: KRYS) will report first quarter 2026 financial results on Monday, May 4, 2026, released prior to the open of U.S. markets.
Management will host a conference call and webcast at 8:30 AM ET on May 4, 2026 to discuss results and provide a business update. A replay will be available for at least 30 days on the company investor website.
Krystal Biotech (NASDAQ: KRYS) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 in Boston. Company executives will participate in a fireside chat at 3:10 pm ET and hold investor meetings that day. A webcast will be available beginning at 3:10 pm ET and posted on the Investors section of the company website.
Krystal Biotech (NASDAQ: KRYS) reported strong 4Q and FY2025 results highlighted by $107.1M in 4Q VYJUVEK revenue and $389.1M for full-year product revenue, with a 94% gross margin. The company ended 2025 with $955.9M in cash and investments and provided FY2026 non-GAAP R&D+SG&A guidance of $175–$195M. Regulatory milestones include FDA RMAT for KB707 (advanced NSCLC) and Fast Track for KB111 (Hailey-Hailey disease). Positive clinical readouts were reported for inhaled KB407 (CF airway transduction 29.4%–42.1%) and multiple registrational study timelines target 2026–2027.
Krystal Biotech (NASDAQ: KRYS) will report fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, before the U.S. market opens. Management will host a conference call and live webcast at 8:30 am ET that day to discuss results and provide a business update.
According to the company, the live webcast is available at the provided webcast link and a replay will be accessible for at least 30 days on the Investors section of the company website.
Krystal Biotech (NASDAQ: KRYS) announced on February 9, 2026 that the FDA granted RMAT designation to KB707 for treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The designation recognizes preliminary clinical activity from the ongoing KYANITE-1 trial and offers expedited development benefits such as rolling review and intensive FDA interaction. Enrollment in KYANITE-1 continues; additional data will be presented at upcoming scientific conferences and the trial is listed as NCT06228326.
Krystal Biotech (NASDAQ: KRYS) provided a business update ahead of its J.P. Morgan Healthcare Conference presentation on Jan 12, 2026, reporting preliminary unaudited Q4 2025 VYJUVEK net revenue of $106M–$107M and full‑year 2025 revenue of $388M–$389M. Cash, cash equivalents, and investments were approximately $955M as of Dec 31, 2025. The company raised enrollment for a registrational NK study from 27 to 60 patients, expects top‑line NK data before end of 2026, and plans multiple registrational readouts in 2026. 2026 objectives include additional European launches, expanding distribution to >40 countries, and advancing a pipeline aimed at four marketed rare‑disease medicines by 2030. 2026 non‑GAAP R&D+SG&A guidance: $175M–$195M.